AAA
JSPR icon

Affinity Asset Advisors’s Jasper Therapeutics JSPR Stock Holding History

Affinity Asset Advisors’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-47,695
Closed -$653K – 89
2023
Q2 		$653K Hold
47,695
– – 0.23% 60
2023
Q1 		$863K Buy
+47,695
New +$882K 0.28% 59

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Affinity Asset Advisors's JSPR Position: Q3 2023 in Review

Affinity Asset Advisors sold out of Jasper Therapeutics (JSPR) in Q3 2023, closing a stake of 47,695 shares — an estimated $653K sold.

Affinity Asset Advisors first reported a position in JSPR in Q1 2023 and held it in 2 quarters. The position peaked at $863K in Q1 2023. 40 funds tracked by Wall St. Rank hold JSPR as of Q3 2023.

  • Affinity Asset Advisors reported no remaining Jasper Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Affinity Asset Advisors sold 47,695 Jasper Therapeutics shares in Q3 2023, an estimated $653K.
  • Affinity Asset Advisors first reported a position in Jasper Therapeutics in Q1 2023 and held it in 2 quarters.
  • Affinity Asset Advisors's Jasper Therapeutics position peaked at $863K in Q1 2023.
  • 40 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2023.

Based on Affinity Asset Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.